GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharos IBio Co Ltd (XKRX:388870) » Definitions » Accounts Payable

Pharos IBio Co (XKRX:388870) Accounts Payable : ₩0.00 Mil (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Pharos IBio Co Accounts Payable?

Pharos IBio Co's Accounts Payable for the quarter that ended in Dec. 2024 was ₩0.00 Mil.


Pharos IBio Co Accounts Payable Historical Data

The historical data trend for Pharos IBio Co's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharos IBio Co Accounts Payable Chart

Pharos IBio Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Accounts Payable
Get a 7-Day Free Trial - - - - -

Pharos IBio Co Quarterly Data
Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Pharos IBio Co Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.


Pharos IBio Co Accounts Payable Related Terms

Thank you for viewing the detailed overview of Pharos IBio Co's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharos IBio Co Business Description

Traded in Other Exchanges
N/A
Address
427beon-gil, Dongan-gu, 1407 and 1408, 38, Heungan-daero, Seongji Star With, Gyeonggi-do, Gwanyang-dong, Anyang-si, KOR
Pharos IBio Co Ltd is a company specializing in new drug development that develops treatments for rare and intractable diseases. It utilizes a new drug development platform based on big data and AI technology. Its product candidate comprises PHI-101-AML, a treatment drug for refractory/relapsed acute myeloid leukemia; PHI-101-OC developed for platinum-resistant/refractory ovarian cancer patients; PHI-101-TNBC is being developed as a drug to treat metastatic triple-negative breast cancer (TNBC); PHI-201; PHI-301; and PHI-501.

Pharos IBio Co Headlines

No Headlines